February 17, 2012 at 15:44 PM EST
Upbeat Preclinical Results For Achillion Pharmaceuticals
Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) reported upbeat preclinical results for its Phase 2 pan-genotypic protease inhibitor ACH-1625 sending the stock price soaring $2.29 to close at $11.04.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here